Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update

Practical Radiation Oncology

Volumn 6, Issue 6, 2016, Pages e219-e234

  Recht, Abram ^a   Comen, Elizabeth A ^b   Fine, Richard E ^c   Fleming, Gini F ^d   Hardenbergh, Patricia H ^e   Ho, Alice Y ^b   Hudis, Clifford A ^b   Hwang, E Shelley ^f   Kirshner, Jeffrey J ^g   Morrow, Monica ^b   Salerno, Kilian E ^h   Sledge, George W ⁱ   Solin, Lawrence J ^j   Spears, Patricia A ^k   Whelan, Timothy J ^l   Somerfield, Mark R ^m   Edge, Stephen B ^h  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Director of Education and Research West Clinic Comprehensive Breast Center   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e Shaw Regional Cancer Center   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g Hematology/Oncology Associates of Central New York   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^j EINSTEIN MEDICAL CENTER   (United States)

^k NORTH CAROLINA STATE UNIVERSITY   (United States)

^l MCMASTER UNIVERSITY   (Canada)

^m AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMERICAN SOCIETY FOR RADIATION ONCOLOGY; AMERICAN SOCIETY OF CLINICAL ONCOLOGY; ARTICLE; AXILLARY LYMPH NODE; AXILLARY LYMPH NODE DISSECTION; BIOPSY; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; HUMAN; INTERNAL MAMMARY NODE; LOCOREGIONAL FAILURE; LYMPH NODE DISSECTION; MASTECTOMY; MEDICAL SOCIETY; ONCOLOGICAL PARAMETERS; PARTIAL MASTECTOMY; POSTMASTECTOMY RADIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; SENTINEL NODE BIOPSY; SOCIETY OF SURGICAL ONCOLOGY; SUPRACLAVICULAR AXILLARY APICAL NODE; SURVIVAL; SYSTEMATIC REVIEW; ADJUVANT RADIOTHERAPY; AXILLA; BREAST NEOPLASMS; CLINICAL DECISION MAKING; EPIDEMIOLOGY; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; MORTALITY; ONCOLOGY; PATHOLOGY; PROCEDURES; RADIATION ONCOLOGY; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SURGICAL ONCOLOGY; TUMOR RECURRENCE; UNITED STATES;

AXILLA; BREAST NEOPLASMS; CLINICAL DECISION-MAKING; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIATION ONCOLOGY; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SOCIETIES, MEDICAL; SURGICAL ONCOLOGY; UNITED STATES;

EID: 84994759967     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2016.08.009     Document Type: Article

References (71)

1. [1] Recht, A, Edge, SB, Solin, LJ, et al. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001), 1539–1569 PubMed.
2. [2] Tseng, YD, Uno, H, Hughes, ME, et al. Biological subtype predicts risk of locoregional recurrence after mastectomy and impact of postmastectomy radiation in a large national database. Int J Radiat Oncol Biol Phys 93 (2015), 622–630, 10.1016/j.ijrobp.2015.07.006 PubMed.
3. [3] Frasier, LL, Holden, S, Holden, T, et al. Temporal trends in postmastectomy radiation therapy and breast reconstruction associated with changes in National Comprehensive Cancer Network guidelines. JAMA Oncol 2 (2016), 95–101, 10.1001/jamaoncol.2015.3717 PubMed.
4. [4] McGale, P, Taylor, C, Correa, C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383 (2014), 2127–2135, 10.1016/S0140-6736(14)60488-8 PubMed.
5. [5] Brackstone, M, Dayes, I, Fletcher, GG, et al. Locoregional Therapy of Locally Advanced Breast Cancer (LABC): Program in Evidence-Based Care Evidence-Based Series No. 1-19. 2014, Cancer Care Ontario, Toronto, Ontario, Canada.
6. [6] Katz, A, Strom, EA, Buchholz, TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 18 (2000), 2817–2827 PubMed.
7. [7] Recht, A, Gray, R, Davidson, NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17 (1999), 1689–1700 PubMed.
8. [8] Taghian, A, Jeong, JH, Mamounas, E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: Results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 22 (2004), 4247–4254, 10.1200/JCO.2004.01.042 PubMed.
9. [9] Truong, PT, Berthelet, E, Lee, J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 103 (2005), 2006–2014, 10.1002/cncr.20969 PubMed.
10. [10] Yildirim, E, Berberoglu, U, Local recurrence in breast carcinoma patients with T(1-2) and 1-3 positive nodes: Indications for radiotherapy. Eur J Surg Oncol 33 (2007), 28–32, 10.1016/j.ejso.2006.10.022 PubMed.
11. [11] Macdonald, SM, Abi-Raad, RF, Alm El-Din, MA, et al. Chest wall radiotherapy: Middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys 75 (2009), 1297–1303, 10.1016/j.ijrobp.2009.01.007 PubMed.
12. [12] Hamamoto, Y, Ohsumi, S, Aogi, K, et al. Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?. Breast Cancer 21 (2014), 177–182, 10.1007/s12282-012-0369-7 PubMed.
13. [13] Huang, CJ, Hou, MF, Chuang, HY, et al. Comparison of clinical outcome of breast cancer patients with T1-2 tumor and one to three positive nodes with or without postmastectomy radiation therapy. Jpn J Clin Oncol 42 (2012), 711–720, 10.1093/jjco/hys080 PubMed.
14. [14] Kim, SI, Park, S, Park, HS, et al. Comparison of treatment outcome between breast-conservation surgery with radiation and total mastectomy without radiation in patients with one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 80 (2011), 1446–1452, 10.1016/j.ijrobp.2010.04.051 PubMed.
15. [15] Sartor, CI, Peterson, BL, Woolf, S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 23 (2005), 30–40, 10.1200/JCO.2005.12.044 PubMed.
16. [16] Moo, TA, McMillan, R, Lee, M, et al. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol 20 (2013), 3169–3174, 10.1245/s10434-013-3117-0 PubMed.
17. [17] Harris, EE, Freilich, J, Lin, HY, et al. The impact of the size of nodal metastases on recurrence risk in breast cancer patients with 1-3 positive axillary nodes after mastectomy. Int J Radiat Oncol Biol Phys 85 (2013), 609–614, 10.1016/j.ijrobp.2012.05.050 PubMed.
18. [18] Botteri, E, Gentilini, O, Rotmensz, N, et al. Mastectomy without radiotherapy: Outcome analysis after 10 years of follow-up in a single institution. Breast Cancer Res Treat 134 (2012), 1221–1228, 10.1007/s10549-012-2044-2 PubMed.
19. [19] Sharma, R, Bedrosian, I, Lucci, A, et al. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17 (2010), 2899–2908, 10.1245/s10434-010-1089-x PubMed.
20. [20] Tendulkar, RD, Rehman, S, Shukla, ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys 83 (2012), e577–e581, 10.1016/j.ijrobp.2012.01.076 PubMed.
21. [21] McBride, A, Allen, P, Woodward, W, et al. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89 (2014), 392–398, 10.1016/j.ijrobp.2014.02.013 PubMed.
22. [22] Lu, C, Xu, H, Chen, X, et al. Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: Yes or no?. Curr Oncol 20 (2013), e585–e592, 10.3747/co.20.1540 PubMed.
23. [23] Cady, B, Stone, MD, Schuler, JG, et al. The new era in breast cancer: Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 131 (1996), 301–308, 10.1001/archsurg.1996.01430150079015 PubMed.
24. [24] Overgaard, M, Jensen, MB, Overgaard, J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999), 1641–1648, 10.1016/S0140-6736(98)09201-0 PubMed.
25. [25] Hennequin, C, Bossard, N, Servagi-Vernat, S, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys 86 (2013), 860–866, 10.1016/j.ijrobp.2013.03.021 [Erratum: Int J Radiat Oncol Biol Phys 89:1145, 2014] PubMed.
26. [26] Whelan, TJ, Olivotto, IA, Parulekar, WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373 (2015), 307–316, 10.1056/NEJMoa1415340 PubMed.
27. [27] Poortmans, PM, Collette, S, Kirkove, C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373 (2015), 317–327, 10.1056/NEJMoa1415369 PubMed.
28. [28] Giordano, SH, Kuo, YF, Freeman, JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97 (2005), 419–424, 10.1093/jnci/dji067 PubMed.
29. [29] Clarke, M, Collins, R, Darby, S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366 (2005), 2087–2106, 10.1016/S0140-6736(05)67887-7 PubMed.
30. [30] McGale, P, Darby, SC, Hall, P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 100 (2011), 167–175, 10.1016/j.radonc.2011.06.016 PubMed.
31. [31] Darby, SC, Ewertz, M, McGale, P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368 (2013), 987–998, 10.1056/NEJMoa1209825 PubMed.
32. [32] Yeboa, DN, Evans, SB, Contemporary breast radiotherapy and cardiac toxicity. Semin Radiat Oncol 26 (2016), 71–78, 10.1016/j.semradonc.2015.09.003 PubMed.
33. [33] Grantzau, T, Overgaard, J, Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients. Radiother Oncol 114 (2015), 56–65, 10.1016/j.radonc.2014.10.004 PubMed.
34. [34] Warren, LE, Miller, CL, Horick, N, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: A prospective cohort study. Int J Radiat Oncol Biol Phys 88 (2014), 565–571, 10.1016/j.ijrobp.2013.11.232 PubMed.
35. [35] Kelley, BP, Ahmed, R, Kidwell, KM, et al. A systematic review of morbidity associated with autologous breast reconstruction before and after exposure to radiotherapy: Are current practices ideal?. Ann Surg Oncol 21 (2014), 1732–1738, 10.1245/s10434-014-3494-z PubMed.
36. [36] Momoh, AO, Ahmed, R, Kelley, BP, et al. A systematic review of complications of implant-based breast reconstruction with prereconstruction and postreconstruction radiotherapy. Ann Surg Oncol 21 (2014), 118–124, 10.1245/s10434-013-3284-z PubMed.
37. [37] Darby, S, McGale, P, Correa, C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378 (2011), 1707–1716 PubMed.
38. [38] Truong, PT, Olivotto, IA, Kader, HA, et al. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005), 1337–1347, 10.1016/j.ijrobp.2004.08.009 PubMed.
39. [39] Yang, PS, Chen, CM, Liu, MC, et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys 77 (2010), 516–522, 10.1016/j.ijrobp.2009.05.016 PubMed.
40. [40] Schairer, C, Mink, PJ, Carroll, L, et al. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96 (2004), 1311–1321, 10.1093/jnci/djh253 PubMed.
41. [41] Kendal, WS, Dying with cancer: The influence of age, comorbidity, and cancer site. Cancer 112 (2008), 1354–1362, 10.1002/cncr.23315 PubMed.
42. [42] Schonberg, MA, Marcantonio, ER, Li, D, et al. Breast cancer among the oldest old: Tumor characteristics, treatment choices, and survival. J Clin Oncol 28 (2010), 2038–2045, 10.1200/JCO.2009.25.9796 PubMed.
43. [43] Ring, A, Sestak, I, Baum, M, et al. Influence of comorbidities and age on risk of death without recurrence: A retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol 29 (2011), 4266–4272, 10.1200/JCO.2011.35.5545 PubMed.
44. [44] Schonberg, MA, Davis, RB, McCarthy, EP, et al. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc 59 (2011), 1444–1451, 10.1111/j.1532-5415.2011.03523.x PubMed.
45. [45] Ross, JG, Hussey, DH, Mayr, NA, et al. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 71 (1993), 3744–3752, 10.1002/1097-0142(19930601)71:11<3744::AID-CNCR2820711144>3.0.CO;2-C PubMed.
46. [46] Chen, AM, Obedian, E, Haffty, BG, Breast-conserving therapy in the setting of collagen vascular disease. Cancer J 7 (2001), 480–491 PubMed.
47. [47] Phan, C, Mindrum, M, Silverman, C, et al. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J 9 (2003), 461–466, 10.1097/00130404-200311000-00005 PubMed.
48. [48] Lin, A, Abu-Isa, E, Griffith, KA, et al. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 113 (2008), 648–653, 10.1002/cncr.23591 PubMed.
49. [49] Lee, CE, Prabhu, V, Slevin, NJ, Collagen vascular diseases and enhanced radiotherapy-induced normal tissue effects: A case report and a review of published studies. Clin Oncol (R Coll Radiol) 23 (2011), 73–78, 10.1016/j.clon.2010.08.030 PubMed.
50. [50] Wallgren, A, Bonetti, M, Gelber, RD, et al. Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group trials I through VII. J Clin Oncol 21 (2003), 1205–1213, 10.1200/JCO.2003.03.130 PubMed.
51. [51] Matsunuma, R, Oguchi, M, Fujikane, T, et al. Influence of lymphatic invasion on locoregional recurrence following mastectomy: Indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. Int J Radiat Oncol Biol Phys 83 (2012), 845–852, 10.1016/j.ijrobp.2011.08.029 PubMed.
52. [52] Kyndi, M, Sørensen, FB, Knudsen, H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26 (2008), 1419–1426, 10.1200/JCO.2007.14.5565 PubMed.
53. [53] Kwan, W, Al-Tourah, AJ, Speers, C, et al. Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease?. Ann Oncol 21 (2010), 988–993, 10.1093/annonc/mdp396 PubMed.
54. [54] Mamounas, EP, Tang, G, Fisher, B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 28 (2010), 1677–1683, 10.1200/JCO.2009.23.7610 PubMed.
55. [55] Wang, SL, Li, YX, Song, YW, et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys 80 (2011), 1095–1101, 10.1016/j.ijrobp.2010.03.038 PubMed.
56. [56] Kneubil, MC, Brollo, J, Botteri, E, et al. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. Eur J Surg Oncol 39 (2013), 260–265, 10.1016/j.ejso.2012.12.004 PubMed.
57. [57] Truong, PT, Olivotto, IA, Speers, CH, et al. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys 58 (2004), 797–804, 10.1016/S0360-3016(03)01626-2 PubMed.
58. [58] Childs, SK, Chen, YH, Duggan, MM, et al. Surgical margins and the risk of local-regional recurrence after mastectomy without radiation therapy. Int J Radiat Oncol Biol Phys 84 (2012), 1133–1138, 10.1016/j.ijrobp.2012.02.048 PubMed.
59. [59] Kunkler, IH, Canney, P, van Tienhoven, G, et al. Elucidating the role of chest wall irradiation in ‘intermediate-risk’ breast cancer: The MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol) 20 (2008), 31–34, 10.1016/j.clon.2007.10.004 PubMed.
60. [60] Lyman, GH, Temin, S, Edge, SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32 (2014), 1365–1383, 10.1200/JCO.2013.54.1177 PubMed.
61. [61] Giuliano, AE, McCall, L, Beitsch, P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252 (2010), 426–432 discussion 432-433. PubMed.
62. [62] Giuliano, AE, Hunt, KK, Ballman, KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 305 (2011), 569–575, 10.1001/jama.2011.90 PubMed.
63. [63] Jagsi, R, Chadha, M, Moni, J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol 32 (2014), 3600–3606, 10.1200/JCO.2014.56.5838 PubMed.
64. [64] Galimberti, V, Cole, BF, Zurrida, S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol 14 (2013), 297–305, 10.1016/S1470-2045(13)70035-4 PubMed.
65. [65] Donker, M, van Tienhoven, G, Straver, ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15 (2014), 1303–1310, 10.1016/S1470-2045(14)70460-7 PubMed.
66. [66] Buchholz, TA, Tucker, SL, Masullo, L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20 (2002), 17–23, 10.1200/JCO.20.1.17 PubMed.
67. [67] Nagar, H, Mittendorf, EA, Strom, EA, et al. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys 81 (2011), 782–787, 10.1016/j.ijrobp.2010.06.027 PubMed.
68. [68] Mamounas, EP, Anderson, SJ, Dignam, JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: Results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30 (2012), 3960–3966, 10.1200/JCO.2011.40.8369 PubMed.
69. [69] Krug, D, Lederer, B, Debus, J, et al. Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. J Clin Oncol, 33, 2015 (suppl; abstr 1008).
70. [70] Thorsen, LB, Offersen, BV, Danø, H, et al. DBCG-IMN: A population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol 34 (2016), 314–320, 10.1200/JCO.2015.63.6456 PubMed.
71. [71] Recht, A, Houlihan, MJ, Axillary lymph nodes and breast cancer: A review. Cancer 76 (1995), 1491–1512, 10.1002/1097-0142(19951101)76:9<1491::AID-CNCR2820760902>3.0.CO;2-8 PubMed.